|
5/15/2013 6:45:04 PM
|
Gilead Sciences Announces Response Data From Phase 2 Study Of Idelalisib
|
|
5/15/2013 11:20:29 AM
|
|
|
5/3/2013 1:00:26 PM
|
Barclays Capital Is Lowering Gilead Sciences Inc. (GILD) FY14 Estimate To 3.17 From 3.21
|
|
5/3/2013 1:00:07 PM
|
Barclays Capital Is Cutting Gilead Sciences Inc. (GILD) FY13 Estimate To 1.95 From 1.98
|
|
5/3/2013 10:15:37 AM
|
|
|
5/2/2013 9:56:01 PM
|
|
|
5/2/2013 7:33:46 PM
|
|
|
5/2/2013 4:26:57 PM
|
|
|
5/2/2013 4:07:44 PM
|
Gilead Sciences Q1 Non-GAAP EPS Rises To $0.48 From $0.45 Last Year
|
|
5/2/2013 3:00:52 PM
|
|
|
5/2/2013 8:33:01 AM
|
Gilead Sciences Plans To Initiate Phase 3 Study Evaluating Eight And 12 Weeks Of Therapy With Sofosbuvir & Ledipasvir
|
|
5/2/2013 7:00:11 AM
|
|
|
4/29/2013 2:27:48 PM
|
|
|
4/29/2013 8:44:13 AM
|
|
|
4/29/2013 8:32:36 AM
|
Gilead Receives Complete Response Letters From FDA For Elvitegravir And Cobicistat
|
|
4/23/2013 6:07:45 AM
|
Gilead Sciences Announces Detailed Results From Four Phase 3 Clinical Trials Evaluating Sofosbuvir For Hepatitis C
|
|
4/15/2013 2:31:45 PM
|
Barclays Capital Is Increasing Gilead Sciences Inc. (GILD) FY14 Estimate To 3.21 From 2.83
|
|
4/15/2013 2:31:35 PM
|
Barclays Capital Is Lowering Gilead Sciences Inc. (GILD) FY13 Estimate To 1.98 From 2.11
|
|
4/9/2013 10:29:05 AM
|
|
|
4/9/2013 9:20:51 AM
|
RBC Capital Markets Is Increasing Gilead Sciences Inc. (GILD) FY14 Rev. Estimate To 13.49 Billion From 13.43 Billion
|